Respiri Limited

CHIA:RSH Stock Report

Market Cap: AU$107.2m

Respiri Management

Management criteria checks 1/4

Respiri's CEO is Marjan Mikel, appointed in Dec 2019, has a tenure of 5.08 years. total yearly compensation is A$758.38K, comprised of 56.5% salary and 43.5% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth A$378.37K. The average tenure of the management team and the board of directors is 3.5 years and 1.8 years respectively.

Key information

Marjan Mikel

Chief executive officer

AU$758.4k

Total compensation

CEO salary percentage56.5%
CEO tenure5yrs
CEO ownership0.4%
Management average tenure3.5yrs
Board average tenure1.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Marjan Mikel's remuneration changed compared to Respiri's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$758kAU$428k

-AU$7m

Mar 31 2024n/an/a

-AU$7m

Dec 31 2023n/an/a

-AU$6m

Sep 30 2023n/an/a

-AU$6m

Jun 30 2023AU$570kAU$428k

-AU$6m

Mar 31 2023n/an/a

-AU$6m

Dec 31 2022n/an/a

-AU$6m

Sep 30 2022n/an/a

-AU$6m

Jun 30 2022AU$607kAU$428k

-AU$7m

Mar 31 2022n/an/a

-AU$7m

Dec 31 2021n/an/a

-AU$8m

Sep 30 2021n/an/a

-AU$9m

Jun 30 2021AU$2mAU$428k

-AU$11m

Mar 31 2021n/an/a

-AU$12m

Dec 31 2020n/an/a

-AU$12m

Sep 30 2020n/an/a

-AU$10m

Jun 30 2020AU$2mAU$187k

-AU$7m

Compensation vs Market: Marjan's total compensation ($USD471.78K) is above average for companies of similar size in the Australian market ($USD286.38K).

Compensation vs Earnings: Marjan's compensation has increased whilst the company is unprofitable.

CEO

Marjan Mikel

5yrs

Tenure

AU$758,383

Compensation

Mr. Marjan Mikel, M.Com, BSc (Hons), Dip Ed, MAICD), serves as Chief Executive Officer and Managing Director at Respiri Limited since December 2, 2019 and serves as its Executive Director since November 25...

Leadership Team

NamePositionTenureCompensationOwnership
Nicholas Smedley
Executive Chairman5.2yrsAU$487.75k1.26%
A$ 1.3m
Marjan Mikel
CEO, MD & Executive Director5yrsAU$758.38k0.35%
A$ 378.4k
Peter Hildebrandt
Chief Operations Officer4.1yrsAU$276.55kno data
George Vlachodimitropoulos
Chief Technology Officer3.3yrsAU$284.75kno data
Samaneh Shirazi
Chief Research Officer5.8yrsAU$208.01kno data
Theo Antonopoulos
Chief Commercial Officer3.5yrsAU$302.66kno data
William Sigsbee
Head of US Operations & Chief Commercial Officer for the US market1.7yrsno datano data
Justin Mouchacca
Joint Company Secretaryless than a yearno datano data
Nova Taylor
Joint Company Secretaryless than a yearno datano data
Noam Gavriely
Medical & Scientific Advisorno dataAU$310.61kno data
Simon Godfrey
Medical & Scientific Advisorno datano datano data

3.5yrs

Average Tenure

Experienced Management: RSH's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nicholas Smedley
Executive Chairman5.2yrsAU$487.75k1.26%
A$ 1.3m
Marjan Mikel
CEO, MD & Executive Director5.1yrsAU$758.38k0.35%
A$ 378.4k
Gerard Criner
Member of Medical Advisory Board1.8yrsno datano data
William Krimsky
Chair of Medical Advisory Board1.8yrsno datano data
Bruce Thompson
Member of Medical & Scientific Advisory Boardno dataAU$1.47kno data
Stephen Selinger
Member of Medical Advisory Board1.8yrsno datano data
Jonathan Hovda
Member of Medical Advisory Board1.8yrsno datano data
Tom Takubo
Non-Executive Directorless than a yearno datano data

1.8yrs

Average Tenure

Experienced Board: RSH's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 14:10
End of Day Share Price 2024/12/31 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Respiri Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Soo RomanoffEdison Investment Research